Bliss GVS Pharma Limited has issued an official clarification to stock exchanges regarding speculative media reports about a potential stake acquisition by Anupam Rasayan. The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on February 13, 2026.

Company's Official Response

The pharmaceutical company addressed news reports published in CNBC आवाज़ with the headline "Bliss GVS में हिस्सा ले सकती है अनुपम रसायन" (Anupam Rasayan may take stake in Bliss GVS). The company categorically stated that these reports appear to be speculative in nature and do not originate from any official communication or confirmation by the company.

Current Status of Reported Development

Bliss GVS Pharma clarified that as of the filing date, no decision or arrangement has been crystallized, finalized, or approved by the company's promoters in relation to the news item. The company emphasized that no information or development warrants disclosure under Regulation 30 of the SEBI regulations at this time.

Regulatory Compliance and Investor Advisory

The company reinforced its commitment to regulatory compliance, stating it is a well-governed and law-compliant entity that has consistently ensured timely and appropriate disclosures to stock exchanges. Bliss GVS Pharma specifically advised:

• Investors and the public should rely only on official disclosures made by the company to stock exchanges
• All disclosures are made in accordance with applicable laws and SEBI regulations
• The clarification aims to prevent establishment of false market sentiment based on speculative reports

Company Information

The clarification was signed by Company Secretary Aditi Bhatt and filed with both the National Stock Exchange of India (Symbol: BLISSGVS) and BSE Limited (Scrip Code: 506197). The company maintains its registered office in Mumbai and operates a manufacturing facility in Palghar district.

Bliss GVS Pharma Limited published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, in leading newspapers as mandated under SEBI Regulation 47. The pharmaceutical company's results were published on February 12, 2026, in English dailies 'The Economic Times & The Free Press Journal' and regional dailies 'Maharashtra Times & Navshakti'.

Financial Performance Overview

The company's financial performance for Q3FY26 showed mixed results across standalone and consolidated operations:

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company demonstrated stronger consolidated performance:

On standalone basis, nine-month total income reached ₹55,268.72 lakh compared to ₹53,805.79 lakh in the previous year, while net profit increased to ₹6,445.19 lakh from ₹5,751.66 lakh.

Interim Dividend Declaration and Regulatory Compliance

The Board declared an interim dividend of 50%, equivalent to ₹0.50 per equity share of face value Re.1 each for financial year 2025-2026:

Publication and Disclosure Requirements

Under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements containing Quick Response Code (QR Code) and weblink to access complete financial results. The publication was made in both English and regional language newspapers to ensure wider accessibility.

Key Performance Metrics

The published results highlighted significant growth in consolidated operations for the nine-month period, with EBITDA reaching ₹11,959.65 lakh, representing a 13% increase. The company's equity share capital stood at ₹1,057.89 lakh as of December 31, 2025.

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, read with relevant rules issued thereunder. Complete financial results are available on stock exchange websites www.bseindia.com and www.nseindia.com , as well as the company's official website.